Report Detail

Pharma & Healthcare Global Antiprotozoal Drugs Market Size, Status and Forecast 2020-2026

  • RnM4208741
  • |
  • 16 September, 2020
  • |
  • Global
  • |
  • 152 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Antiprotozoal Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Amoebic Dysentery
    • 1.2.3 Antimalarial Drug
    • 1.2.4 Leishmaniasis & Chagas Disease
  • 1.3 Market by Application
    • 1.3.1 Global Antiprotozoal Drugs Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinic
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Antiprotozoal Drugs Market Perspective (2015-2026)
  • 2.2 Global Antiprotozoal Drugs Growth Trends by Regions
    • 2.2.1 Antiprotozoal Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Antiprotozoal Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Antiprotozoal Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Antiprotozoal Drugs Players by Market Size
    • 3.1.1 Global Top Antiprotozoal Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Antiprotozoal Drugs Revenue Market Share by Players (2015-2020)
  • 3.2 Global Antiprotozoal Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Antiprotozoal Drugs Revenue
  • 3.4 Global Antiprotozoal Drugs Market Concentration Ratio
    • 3.4.1 Global Antiprotozoal Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Antiprotozoal Drugs Revenue in 2019
  • 3.5 Key Players Antiprotozoal Drugs Area Served
  • 3.6 Key Players Antiprotozoal Drugs Product Solution and Service
  • 3.7 Date of Enter into Antiprotozoal Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Antiprotozoal Drugs Breakdown Data by Type (2015-2026)

  • 4.1 Global Antiprotozoal Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Antiprotozoal Drugs Forecasted Market Size by Type (2021-2026)

5 Antiprotozoal Drugs Breakdown Data by Application (2015-2026)

  • 5.1 Global Antiprotozoal Drugs Historic Market Size by Application (2015-2020)
  • 5.2 Global Antiprotozoal Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Antiprotozoal Drugs Market Size (2015-2026)
  • 6.2 North America Antiprotozoal Drugs Market Size by Type (2015-2020)
  • 6.3 North America Antiprotozoal Drugs Market Size by Application (2015-2020)
  • 6.4 North America Antiprotozoal Drugs Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Antiprotozoal Drugs Market Size (2015-2026)
  • 7.2 Europe Antiprotozoal Drugs Market Size by Type (2015-2020)
  • 7.3 Europe Antiprotozoal Drugs Market Size by Application (2015-2020)
  • 7.4 Europe Antiprotozoal Drugs Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Antiprotozoal Drugs Market Size (2015-2026)
  • 8.2 China Antiprotozoal Drugs Market Size by Type (2015-2020)
  • 8.3 China Antiprotozoal Drugs Market Size by Application (2015-2020)
  • 8.4 China Antiprotozoal Drugs Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Antiprotozoal Drugs Market Size (2015-2026)
  • 9.2 Japan Antiprotozoal Drugs Market Size by Type (2015-2020)
  • 9.3 Japan Antiprotozoal Drugs Market Size by Application (2015-2020)
  • 9.4 Japan Antiprotozoal Drugs Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 India

  • 10.1 India Antiprotozoal Drugs Market Size (2015-2026)
  • 10.2 India Antiprotozoal Drugs Market Size by Type (2015-2020)
  • 10.3 India Antiprotozoal Drugs Market Size by Application (2015-2020)
  • 10.4 India Antiprotozoal Drugs Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Sanofi
    • 11.1.1 Sanofi Company Details
    • 11.1.2 Sanofi Business Overview
    • 11.1.3 Sanofi Antiprotozoal Drugs Introduction
    • 11.1.4 Sanofi Revenue in Antiprotozoal Drugs Business (2015-2020))
    • 11.1.5 Sanofi Recent Development
  • 11.2 Akthelia Pharmaceuticals Ltd
    • 11.2.1 Akthelia Pharmaceuticals Ltd Company Details
    • 11.2.2 Akthelia Pharmaceuticals Ltd Business Overview
    • 11.2.3 Akthelia Pharmaceuticals Ltd Antiprotozoal Drugs Introduction
    • 11.2.4 Akthelia Pharmaceuticals Ltd Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.2.5 Akthelia Pharmaceuticals Ltd Recent Development
  • 11.3 GlaxoSmithKline Plc
    • 11.3.1 GlaxoSmithKline Plc Company Details
    • 11.3.2 GlaxoSmithKline Plc Business Overview
    • 11.3.3 GlaxoSmithKline Plc Antiprotozoal Drugs Introduction
    • 11.3.4 GlaxoSmithKline Plc Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.3.5 GlaxoSmithKline Plc Recent Development
  • 11.4 Immuron Ltd
    • 11.4.1 Immuron Ltd Company Details
    • 11.4.2 Immuron Ltd Business Overview
    • 11.4.3 Immuron Ltd Antiprotozoal Drugs Introduction
    • 11.4.4 Immuron Ltd Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.4.5 Immuron Ltd Recent Development
  • 11.5 Microbiotix Inc
    • 11.5.1 Microbiotix Inc Company Details
    • 11.5.2 Microbiotix Inc Business Overview
    • 11.5.3 Microbiotix Inc Antiprotozoal Drugs Introduction
    • 11.5.4 Microbiotix Inc Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.5.5 Microbiotix Inc Recent Development
  • 11.6 Protein Potential LLC
    • 11.6.1 Protein Potential LLC Company Details
    • 11.6.2 Protein Potential LLC Business Overview
    • 11.6.3 Protein Potential LLC Antiprotozoal Drugs Introduction
    • 11.6.4 Protein Potential LLC Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.6.5 Protein Potential LLC Recent Development
  • 11.7 Dr. Reddy’s Laboratories
    • 11.7.1 Dr. Reddy’s Laboratories Company Details
    • 11.7.2 Dr. Reddy’s Laboratories Business Overview
    • 11.7.3 Dr. Reddy’s Laboratories Antiprotozoal Drugs Introduction
    • 11.7.4 Dr. Reddy’s Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.7.5 Dr. Reddy’s Laboratories Recent Development
  • 11.8 Mission Pharmacal
    • 11.8.1 Mission Pharmacal Company Details
    • 11.8.2 Mission Pharmacal Business Overview
    • 11.8.3 Mission Pharmacal Antiprotozoal Drugs Introduction
    • 11.8.4 Mission Pharmacal Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.8.5 Mission Pharmacal Recent Development
  • 11.9 Aceto Corp.
    • 11.9.1 Aceto Corp. Company Details
    • 11.9.2 Aceto Corp. Business Overview
    • 11.9.3 Aceto Corp. Antiprotozoal Drugs Introduction
    • 11.9.4 Aceto Corp. Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.9.5 Aceto Corp. Recent Development
  • 11.10 Mylan Pharmaceuticals
    • 11.10.1 Mylan Pharmaceuticals Company Details
    • 11.10.2 Mylan Pharmaceuticals Business Overview
    • 11.10.3 Mylan Pharmaceuticals Antiprotozoal Drugs Introduction
    • 11.10.4 Mylan Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 11.10.5 Mylan Pharmaceuticals Recent Development
  • 11.11 Impax Laboratories
    • 10.11.1 Impax Laboratories Company Details
    • 10.11.2 Impax Laboratories Business Overview
    • 10.11.3 Impax Laboratories Antiprotozoal Drugs Introduction
    • 10.11.4 Impax Laboratories Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.11.5 Impax Laboratories Recent Development
  • 11.12 Pfizer
    • 10.12.1 Pfizer Company Details
    • 10.12.2 Pfizer Business Overview
    • 10.12.3 Pfizer Antiprotozoal Drugs Introduction
    • 10.12.4 Pfizer Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.12.5 Pfizer Recent Development
  • 11.13 Lupin Pharmaceuticals
    • 10.13.1 Lupin Pharmaceuticals Company Details
    • 10.13.2 Lupin Pharmaceuticals Business Overview
    • 10.13.3 Lupin Pharmaceuticals Antiprotozoal Drugs Introduction
    • 10.13.4 Lupin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.13.5 Lupin Pharmaceuticals Recent Development
  • 11.14 Glenmark Pharmaceuticals
    • 10.14.1 Glenmark Pharmaceuticals Company Details
    • 10.14.2 Glenmark Pharmaceuticals Business Overview
    • 10.14.3 Glenmark Pharmaceuticals Antiprotozoal Drugs Introduction
    • 10.14.4 Glenmark Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.14.5 Glenmark Pharmaceuticals Recent Development
  • 11.15 Sun Pharmaceutical
    • 10.15.1 Sun Pharmaceutical Company Details
    • 10.15.2 Sun Pharmaceutical Business Overview
    • 10.15.3 Sun Pharmaceutical Antiprotozoal Drugs Introduction
    • 10.15.4 Sun Pharmaceutical Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.15.5 Sun Pharmaceutical Recent Development
  • 11.16 Heritage Pharmaceuticals
    • 10.16.1 Heritage Pharmaceuticals Company Details
    • 10.16.2 Heritage Pharmaceuticals Business Overview
    • 10.16.3 Heritage Pharmaceuticals Antiprotozoal Drugs Introduction
    • 10.16.4 Heritage Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.16.5 Heritage Pharmaceuticals Recent Development
  • 11.17 Gilead Sciences
    • 10.17.1 Gilead Sciences Company Details
    • 10.17.2 Gilead Sciences Business Overview
    • 10.17.3 Gilead Sciences Antiprotozoal Drugs Introduction
    • 10.17.4 Gilead Sciences Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.17.5 Gilead Sciences Recent Development
  • 11.18 Johnson & Johnson
    • 10.18.1 Johnson & Johnson Company Details
    • 10.18.2 Johnson & Johnson Business Overview
    • 10.18.3 Johnson & Johnson Antiprotozoal Drugs Introduction
    • 10.18.4 Johnson & Johnson Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.18.5 Johnson & Johnson Recent Development
  • 11.19 Bristol-Myers Squibb
    • 10.19.1 Bristol-Myers Squibb Company Details
    • 10.19.2 Bristol-Myers Squibb Business Overview
    • 10.19.3 Bristol-Myers Squibb Antiprotozoal Drugs Introduction
    • 10.19.4 Bristol-Myers Squibb Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.19.5 Bristol-Myers Squibb Recent Development
  • 11.20 Profounda
    • 10.20.1 Profounda Company Details
    • 10.20.2 Profounda Business Overview
    • 10.20.3 Profounda Antiprotozoal Drugs Introduction
    • 10.20.4 Profounda Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.20.5 Profounda Recent Development
  • 11.21 Knight Therapeutics
    • 10.21.1 Knight Therapeutics Company Details
    • 10.21.2 Knight Therapeutics Business Overview
    • 10.21.3 Knight Therapeutics Antiprotozoal Drugs Introduction
    • 10.21.4 Knight Therapeutics Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.21.5 Knight Therapeutics Recent Development
  • 11.22 Albert David
    • 10.22.1 Albert David Company Details
    • 10.22.2 Albert David Business Overview
    • 10.22.3 Albert David Antiprotozoal Drugs Introduction
    • 10.22.4 Albert David Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.22.5 Albert David Recent Development
  • 11.23 Wanlong
    • 10.23.1 Wanlong Company Details
    • 10.23.2 Wanlong Business Overview
    • 10.23.3 Wanlong Antiprotozoal Drugs Introduction
    • 10.23.4 Wanlong Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.23.5 Wanlong Recent Development
  • 11.24 Fangsheng
    • 10.24.1 Fangsheng Company Details
    • 10.24.2 Fangsheng Business Overview
    • 10.24.3 Fangsheng Antiprotozoal Drugs Introduction
    • 10.24.4 Fangsheng Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.24.5 Fangsheng Recent Development
  • 11.25 KPC Pharmaceuticals
    • 10.25.1 KPC Pharmaceuticals Company Details
    • 10.25.2 KPC Pharmaceuticals Business Overview
    • 10.25.3 KPC Pharmaceuticals Antiprotozoal Drugs Introduction
    • 10.25.4 KPC Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.25.5 KPC Pharmaceuticals Recent Development
  • 11.26 Guilin Pharmaceuticals
    • 10.26.1 Guilin Pharmaceuticals Company Details
    • 10.26.2 Guilin Pharmaceuticals Business Overview
    • 10.26.3 Guilin Pharmaceuticals Antiprotozoal Drugs Introduction
    • 10.26.4 Guilin Pharmaceuticals Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.26.5 Guilin Pharmaceuticals Recent Development
  • 11.27 Pude Pharmaceutica
    • 10.27.1 Pude Pharmaceutica Company Details
    • 10.27.2 Pude Pharmaceutica Business Overview
    • 10.27.3 Pude Pharmaceutica Antiprotozoal Drugs Introduction
    • 10.27.4 Pude Pharmaceutica Revenue in Antiprotozoal Drugs Business (2015-2020)
    • 10.27.5 Pude Pharmaceutica Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Antiprotozoal Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antiprotozoal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    by Diseases
    Amoebic Dysentery
    Antimalarial Drug
    Leishmaniasis & Chagas Disease
    by Drugs
    Metronidazole
    Atovaquone
    Benznidazole
    Dehydroemetine
    Eflornithine
    Emetine
    Fenbendazole
    Iodoquinol
    Melarsoprol
    Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)

    Market segment by Application, split into
    Hospital
    Clinic

    Based on regional and country-level analysis, the Antiprotozoal Drugs market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Antiprotozoal Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Sanofi
    Akthelia Pharmaceuticals Ltd
    GlaxoSmithKline Plc
    Immuron Ltd
    Microbiotix Inc
    Protein Potential LLC
    Dr. Reddy’s Laboratories
    Mission Pharmacal
    Aceto Corp.
    Mylan Pharmaceuticals
    Impax Laboratories
    Pfizer
    Lupin Pharmaceuticals
    Glenmark Pharmaceuticals
    Sun Pharmaceutical
    Heritage Pharmaceuticals
    Gilead Sciences
    Johnson & Johnson
    Bristol-Myers Squibb
    Profounda
    Knight Therapeutics
    Albert David
    Wanlong
    Fangsheng
    KPC Pharmaceuticals
    Guilin Pharmaceuticals


    Summary:
    Get latest Market Research Reports on Antiprotozoal Drugs. Industry analysis & Market Report on Antiprotozoal Drugs is a syndicated market report, published as Global Antiprotozoal Drugs Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Antiprotozoal Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    3,010.96
    4,516.44
    6,021.92
    3,292.78
    4,939.17
    6,585.56
    407,429.10
    611,143.65
    814,858.20
    286,697.19
    430,045.79
    573,394.38
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report